Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response

Translational Psychiatry

Volumn 6, Issue 9, 2016, Pages

  Li, Q S ^a   Tian, C ^b   Seabrook, G R ^c   Drevets, W C ^a   Narayan, V A ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b 23andMe Inc ^*  (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DOPAMINE UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VASCULOTROPIN A;

ADULT; CHROMOSOME 4; CIRCADIAN RHYTHM; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG RESISTANCE; FEMALE; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HUMAN; MALE; MIDDLE AGED; NERVE CELL PLASTICITY; QUESTIONNAIRE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; BUPROPION; CHROMOSOMES, HUMAN, PAIR 4; CIRCADIAN RHYTHM; CITALOPRAM; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOPAMINE UPTAKE INHIBITORS; DRUG RESISTANCE; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; NEURONAL PLASTICITY; SEROTONIN UPTAKE INHIBITORS; SIGNAL TRANSDUCTION; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85021056104     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/TP.2016.171     Document Type: Article

References (39)

1. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 2009; 66: 966–975.
2. Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010; 167: 555–564.
3. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010; 67: 133–138.
4. Ji Y, Biernacka JM, Hebbring S, Chai Y, Jenkins GD, Batzler A et al. Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. Pharmacogenomics J 2013; 13: 456–463.
5. GENDEP Investigators, MARS Investigators, STAR*D Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry 2013; 170: 207–217.
6. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008; 455: 894–902.
7. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 5th edn Washington DC, USA, 2013.
8. Do CB, Tung JY, Dorfman E, Kiefer AK, Drabant EM, Francke U et al. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet 2011; 7: e1002141.
9. Eriksson N, Macpherson JM, Tung JY, Hon LS, Naughton B, Saxonov S et al. Webbased, participant-driven studies yield novel genetic associations for common traits. PLoS Genet 2010; 6: e1000993.
10. Eriksson N, Tung JY, Kiefer AK, Hinds DA, Francke U, Mountain JL et al. Novel associations for hypothyroidism include known autoimmune risk loci. PLoS ONE 2012; 7: e34442.
11. Kiefer AK, Tung JY, Do CB, Hinds DA, Mountain JL, Francke U et al. Genome-wide analysis points to roles for extracellular matrix remodeling, the visual cycle, and neuronal development in myopia. PLoS Genet 2013; 9: e1003299.
12. Tung JY, Do CB, Hinds DA, Kiefer AK, Macpherson JM, Chowdry AB et al. Efficient replication of over 180 genetic associations with self-reported medical data. PLoS ONE 2011; 6: e23473.
13. Hromatka BS, Tung JY, Kiefer AK, Do CB, Hinds DA, Eriksson N. Genetic variants associated with motion sickness point to roles for inner ear development, neurological processes and glucose homeostasis. Hum Mol Genet 2015; 24: 2700–2708.
14. Hu Y, Shmygelska A, Tran D, Eriksson N, Tung JY, Hinds DA. GWAS of 89,283 individuals identifies genetic variants associated with self-reporting of being a morning person. Nat Commun 2016; 7: 10448.
15. Genomes Project C, Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM et al. A map of human genome variation from population-scale sequencing. Nature 2010; 467: 1061–1073.
16. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013; 381: 1371–1379.
17. Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM et al. A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry 2013; 18: 497–511.
18. Psychiatric GWAS Consortium Bipolar Disorder Working Group. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet 2011; 43: 977–983.
19. Schizophrenia Psychiatric Genome-Wide Association Study Consortium. Genomewide association study identifies five new schizophrenia loci. Nat Genet 2011; 43: 969–976.
20. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J et al. Schizophrenia Working Group of the Psychiatric Genomics C LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet 2015; 47: 291–295.
21. Lee PH, O'Dushlaine C, Thomas B, Purcell SM. INRICH: interval-based enrichment analysis for genome-wide association studies. Bioinformatics 2012; 28: 1797–1799.
22. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 2010; 26: 2336–2337.
23. Hibar DP, Stein JL, Renteria ME, Arias-Vasquez A, Desrivieres S, Jahanshad N et al. Common genetic variants influence human subcortical brain structures. Nature 2015; 520: 224–229.
24. Schmaal L, Veltman DJ, van Erp TG, Samann PG, Frodl T, Jahanshad N et al. Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group. Mol Psychiatry 2015; 21: 806–812.
25. Ramasamy A, Trabzuni D, Guelfi S, Varghese V, Smith C, Walker R et al. Genetic variability in the regulation of gene expression in ten regions of the human brain. Nat Neurosci 2014; 17: 1418–1428.
26. Hida A, Kitamura S, Katayose Y, Kato M, Ono H, Kadotani H et al. Screening of clock gene polymorphisms demonstrates association of a PER3 polymorphism with morningness-eveningness preference and circadian rhythm sleep disorder. Sci Rep 2014; 4: 6309.
27. Wang X, Mozhui K, Li Z, Mulligan MK, Ingels JF, Zhou X et al. A promoter polymorphism in the Per3 gene is associated with alcohol and stress response. Transl Psychiatry 2012; 2: e73.
28. Karthikeyan R, Marimuthu G, Ramasubramanian C, Arunachal G, BaHammam AS, Spence DW et al. Association of Per3 length polymorphism with bipolar I disorder and schizophrenia. Neuropsychiatr Dis Treat 2014; 10: 2325–2330.
29. Maglione JE, Nievergelt CM, Parimi N, Evans DS, Ancoli-Israel S, Stone KL et al. Associations of PER3 and RORA circadian gene polymorphisms and depressive symptoms in older adults. Am J Geriatr Psychiatry 2015; 23: 1075–1087.
30. Abdallah CG, Jiang L, De Feyter HM, Fasula M, Krystal JH, Rothman DL et al. Glutamate metabolism in major depressive disorder. Am J Psychiatry 2014; 171: 1320–1327.
31. Menke A, Samann P, Kloiber S, Czamara D, Lucae S, Hennings J et al. Polymorphisms within the metabotropic glutamate receptor 1 gene are associated with depression phenotypes. Psychoneuroendocrinology 2012; 37: 565–575.
32. Heuser I, Yassouridis A, Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 1994; 28: 341–356.
33. Shin S, Kwon O, Kang JI, Kwon S, Oh S, Choi J et al. mGluR5 in the nucleus accumbens is critical for promoting resilience to chronic stress. Nat Neurosci 2015; 18: 1017–1024.
34. Oliet SH, Mothet JP. Regulation of N-methyl-D-aspartate receptors by astrocytic D-serine. Neuroscience 2009; 158: 275–283.
35. Henneberger C, Papouin T, Oliet SH, Rusakov DA. Long-term potentiation depends on release of D-serine from astrocytes. Nature 2010; 463: 232–236.
36. Carvalho AF, Kohler CA, McIntyre RS, Knochel C, Brunoni AR, Thase ME et al. Peripheral vascular endothelial growth factor as a novel depression biomarker: A meta-analysis. Psychoneuroendocrinology 2015; 62: 18–26.
37. Turecki G, Grof P, Cavazzoni P, Duffy A, Grof E, Ahrens B et al. Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder. Mol Psychiatry 1998; 3: 534–538.
38. Rohayem J, Bayle JF, Richa S. [Predictors of prophylactic response to lithium]. Encephale 2008; 34: 394–399.
39. Ikeda A, Kato T. Biological predictors of lithium response in bipolar disorder. Psychiatry Clin Neurosci 2003; 57: 243–250.